Wanbury News

Wanbury Strengthens Coriminic Brand with Pediatric Drops

Wanbury launches Coriminic CPM Drops and NS Nasal Drops for children, addressing DCGI restrictions on fixed-dose cold combinations under Regulation 30 compliance.

Wanbury Launches New Cold Medicine Drops for Kids

Wanbury introduces Coriminic CPM Drops and Coriminic NS Nasal Drops for children, targeting regulations on cold medicines for kids under 4 years in the ₹861 crore market.

Wanbury Gets Brazil Approval for Sertraline Form II

Wanbury secures regulatory approval for Sertraline Form II in Brazil, where it holds 75% market share. Company also gets approval for special grade Metformin with ₹15 crore annual revenue potential.

Wanbury Q3FY26 Results: Profit Surges 1194% YoY

Wanbury Limited reported exceptional Q3FY26 performance with profit after tax jumping to ₹1,575.90 lakhs from ₹121.77 lakhs YoY. Revenue grew 21.7% to ₹16,244.75 lakhs.

Wanbury Launches Four New Anesthetic APIs at Tanuku

Wanbury Limited announces launch of four new anesthetic APIs at its Tanuku facility, targeting ₹100 crore revenue in FY 2026-27, expected to add 15% to company's annual revenue.